A
Ann Williams
Researcher at Public Health England
Publications - 43
Citations - 1385
Ann Williams is an academic researcher from Public Health England. The author has contributed to research in topics: Tuberculosis & Mycobacterium tuberculosis. The author has an hindex of 20, co-authored 41 publications receiving 1143 citations.
Papers
More filters
Journal ArticleDOI
Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials.
Ainhoa Arbues,Ainhoa Arbues,Juan Ignacio Aguilo,Juan Ignacio Aguilo,Jesús Gonzalo-Asensio,Jesús Gonzalo-Asensio,Dessislava Marinova,Dessislava Marinova,Santiago Uranga,Santiago Uranga,Eugenia Puentes,Conchita Fernandez,Alberto Parra,Pere-Joan Cardona,Pere-Joan Cardona,Cristina Vilaplana,Cristina Vilaplana,Vicente Ausina,Vicente Ausina,Ann Williams,Simon Clark,Wladimir Malaga,Wladimir Malaga,Christophe Guilhot,Christophe Guilhot,Brigitte Gicquel,Carlos Martin,Carlos Martin +27 more
TL;DR: MTBVAC is an attenuated Mycobacterium tuberculosis vaccine candidate genetically engineered to fulfil the Geneva consensus requirements to enter human clinical trials and is believed to be the first live attenuated M. tuberculosis vaccine to enter clinical evaluation.
Journal ArticleDOI
Alternative BCG delivery strategies improve protection against Mycobacterium tuberculosis in non-human primates: Protection associated with mycobacterial antigen-specific CD4 effector memory T-cell populations.
Sally Sharpe,Andrew White,Charlotte Sarfas,Laura Sibley,Fergus V. Gleeson,Anthony McIntyre,Randall J. Basaraba,Simon Clark,Graham Hall,Emma Rayner,Ann Williams,Philip Marsh,Mike Dennis +12 more
TL;DR: This study demonstrates the protective efficacy of IV BCG vaccination in rhesus macaques, offering a valuable tool for the interrogation of immunological mechanisms and potential correlates of protection.
Journal ArticleDOI
A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data.
Helen McShane,Ann Williams +1 more
TL;DR: The efficacy in animal models of the MVA85A candidate vaccine is reviewed in light of recent human efficacy data and refinements to the preclinical models are proposed with the aim of increasing their predictive value for human efficacy.
Journal ArticleDOI
Progress and challenges in TB vaccine development
Gerald Voss,Danilo Casimiro,Danilo Casimiro,Olivier Neyrolles,Ann Williams,Stefan H. E. Kaufmann,Helen McShane,Mark Hatherill,Helen A. Fletcher +8 more
TL;DR: The Bacille Calmette Guerin (BCG) vaccine can provide decades of protection against tuberculosis (TB) disease, and although imperfect, BCG is proof that vaccine mediated protection against TB is a possibility.
Journal ArticleDOI
Animal Models of Tuberculosis: Guinea Pigs
TL;DR: Demonstration of the protective efficacy of vaccines in the low-dose aerosol guinea pig model is an important component of the preclinical data package for novel vaccines in development, and there is a continual need to improve the model to facilitate progression of vaccines to the clinic.